Nektar Therapeutics (NKTR)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 10:59AM EDT. Market open.
| Previous close | 1.3200 |
| Open | 1.3300 |
| Bid | 1.3300 x 1200 |
| Ask | 1.3800 x 700 |
| Day's range | 1.3200 - 1.3600 |
| 52-week range | 0.4100 - 1.7500 |
| Volume | |
| Avg. volume | 2,551,675 |
| Market cap | 248.802M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4500 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.00 |
ZacksNektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PR NewswireNektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
ZacksNektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
© 2024 Yahoo. All rights reserved.